JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

    J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell NYnJeG1{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEXJdJZKdmirYnn0bY9vKG:oIHj1cYFvKEuXLUG5MVE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57M{KzOkDPxE1? MUfTRW5ITVJ?
H4 cell M{\SVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{\vT2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC2O|A4KM7:TR?= NFnGXnNUSU6JRWK=
KGN cell Mn7HS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2ryeWlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NlA2KM7:TR?= Ml7VV2FPT0WU
786-0 cell M2Hwbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1exRmlvcGmkaYTpc44hd2ZiaIXtZY4hPzh4LUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlczQTh7IN88US=> MWLTRW5ITVJ?
769-P cell NULGPHNFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlvETY5pcWKrdHnvckBw\iCqdX3hckA4PjlvUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPFIzOjRizszN MVPTRW5ITVJ?
K5 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3m3dmlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkCxOlI1KM7:TR?= NV3PfphHW0GQR1XS
MLMA cell NI\XPHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3;G[WlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xOzJzNzFOwG0> MVfTRW5ITVJ?
MLMA cell M4jBXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGnZR5ZKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI5PzB|IN88US=> MonyV2FPT0WU
EW-7 cell NGXUcmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXzJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkOyOlk2KM7:TR?= MVHTRW5ITVJ?
SW1088 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWS4dmVsUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjhyNkWxJO69VQ>? M4jvSHNCVkeHUh?=
MC-IXC cell NGHMT4RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlXJTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg4Pzl{IN88US=> MmXqV2FPT0WU
NCI-H2052 cell NFr6bHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2T0b2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFUzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5yOEG1O{DPxE1? MnL1V2FPT0WU
IGR-1 cell NW\5TZFlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3fVO2lvcGmkaYTpc44hd2ZiaIXtZY4hUUeULUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlEzODJ6IN88US=> MYLTRW5ITVJ?
DSH1 cell Ml\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGRUUDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkK0Nlk3KM7:TR?= MnztV2FPT0WU
PA-1 cell NVP6SJJJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M37heWlvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuN|AxPToQvF2= M3O1RXNCVkeHUh?=
SK-MEL-3 cell Mn73S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M37BXmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjNzMkC3JO69VQ>? MlP6V2FPT0WU
SW900 cell M1jvSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3;WXWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=> NHSxeHBUSU6JRWK=
CAKI-1 cell M4H4[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYXJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI4OzhizszN MoK4V2FPT0WU
ES1 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNUK4PVch|ryP MVvTRW5ITVJ?
SK-N-DZ cell NYPENWYzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFrySFVKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ{NUm1JO69VQ>? MWLTRW5ITVJ?
RH-1 cell M2r0cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFn5eYJKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY5PDZ|IN88US=> NFL3OGFUSU6JRWK=
ES8 cell MnmxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjEUHZKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlk4ODJizszN MlO0V2FPT0WU
NEC8 cell Mlv1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYnJcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lke2PVgzKM7:TR?= NEPi[|ZUSU6JRWK=
LNCaP-Clone-FGC cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVXJcohq[mm2aX;uJI9nKGi3bXHuJGxPS2GSLVPsc45mNU[JQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFM2OzZizszN MnTqV2FPT0WU
HCE-4 cell NYjoNmpYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFryNlRKdmirYnn0bY9vKG:oIHj1cYFvKEiFRT20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{46QDB5IN88US=> MWLTRW5ITVJ?
U-118-MG cell MoTwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFjaUXhKdmirYnn0bY9vKG:oIHj1cYFvKFVvMUG4MW1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yMUC2OkDPxE1? MmrLV2FPT0WU
GI-ME-N cell NYPuO2tHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2DTbGlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvTVWtUkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODh5OU[g{txO M3nmXXNCVkeHUh?=
LB1047-RCC cell NIq0VpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2qwemlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMU[xOFMh|ryP NXjjUVBqW0GQR1XS
HT-1080 cell M2Doemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1f0O2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTl7MkGg{txO MmXTV2FPT0WU
NB69 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXKwTGdpUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{PTB2NzFOwG0> M3uxSHNCVkeHUh?=
NCI-H1693 cell Mm\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3rnV2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlk{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC52NEi5OUDPxE1? MkP1V2FPT0WU
HSC-3 cell M3PjZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4DNfmlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ6QTN|IN88US=> MWfTRW5ITVJ?
MDA-MB-231 cell NITTXoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV3OEm5JO69VQ>? NHrQVYZUSU6JRWK=
HOS cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYjlU3BqUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5PjNizszN M{XmZ3NCVkeHUh?=
BT-549 cell NVnKVFd4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnTUTY5pcWKrdHnvckBw\iCqdX3hckBDXC13NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5QDdizszN NV\3XYdTW0GQR1XS
NB17 cell NVXiWYdGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJG5DOTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke4PVc3KM7:TR?= M4XCWnNCVkeHUh?=
5637 cell NHrmS2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmnJTY5pcWKrdHnvckBw\iCqdX3hckA2PjN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63PVY2OiEQvF2= MYXTRW5ITVJ?
OVCAR-8 cell MkHyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVjkeFlIUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57MkSzOkDPxE1? MUPTRW5ITVJ?
G-402 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWO4SWpwUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTNyM{Wg{txO MmHSV2FPT0WU
BB30-HNC cell NXHQOVB{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xPzJzODFOwG0> M1O3bnNCVkeHUh?=
HCC1806 cell MlSyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYXHRVJVUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxPFA3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yOEOzPUDPxE1? MmLRV2FPT0WU
COLO-800 cell NF\3ZWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGXrTlhKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5zMk[0JO69VQ>? NX;YbJVFW0GQR1XS
FADU cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1Lwd2lvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|Y2PTdizszN M2P4VnNCVkeHUh?=
NCI-H1651 cell NFnHbJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWmwe2pPUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkO5OFA6KM7:TR?= MUHTRW5ITVJ?
AGS cell NIP5OY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIiyfWVKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFc4OTFizszN MXfTRW5ITVJ?
CHP-212 cell M2D3WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NETodGJKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>? NUHJfmpIW0GQR1XS
YAPC cell M4T2UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEf6bHhKdmirYnn0bY9vKG:oIHj1cYFvKFmDUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=> MXzTRW5ITVJ?
GOTO cell NI\6RpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGdQXE9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS5OVc3KM7:TR?= NEHuWGFUSU6JRWK=
KYSE-510 cell MkXhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkfVTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTFzIN88US=> M1nlO3NCVkeHUh?=
NCI-H2342 cell NV\DfnVHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn3PTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV|Mke4JO69VQ>? NETUXWdUSU6JRWK=
BFTC-905 cell MnTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh|NTFOwG0> M2XadXNCVkeHUh?=
EW-16 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkGyTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxQTNizszN MkXiV2FPT0WU
SK-MEL-30 cell MmPpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkHCTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njd2NUSzJO69VQ>? NYnVdJR7W0GQR1XS
HLE cell M4mybWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{e0PFkh|ryP NEL6c4tUSU6JRWK=
T98G cell M2m2VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX7xUZJ5UW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44QTZ|NTFOwG0> NYDvSo9[W0GQR1XS
HUTU-80 cell NV7hZnNbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg1OjJ6IN88US=> NVO3WnRDW0GQR1XS
NOS-1 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUDMZ4oxUW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTR5Nk[g{txO NFXUbHlUSU6JRWK=
SW780 cell Ml7TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVHZelRiUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTZ7NEmg{txO Mk\NV2FPT0WU
KYSE-180 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVHjTZNlUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE5OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOUe2OVQh|ryP NGT4bGNUSU6JRWK=
MDA-MB-361 cell NEntb21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVXtfnZ3UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65PFY1PyEQvF2= MmHVV2FPT0WU
SNU-C2B cell MonIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXfNZ4JoUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtR|JDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5yMUGzPEDPxE1? MmXNV2FPT0WU
NCI-H661 cell NF;FOppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3zaOGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB4OUSg{txO M3:yUHNCVkeHUh?=
OE33 cell NYHseJhrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGjRbGdKdmirYnn0bY9vKG:oIHj1cYFvKE:HM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE1Ozh7IN88US=> NFj0fnRUSU6JRWK=
TYK-nu cell NXfnSIRVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUX1eXJFUW6qaXLpeIlwdiCxZjDoeY1idiCWWVutcpUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjJzOE[zJO69VQ>? M{fhOHNCVkeHUh?=
COLO-792 cell NE\pXFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NILuOIlKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{NUKxPUDPxE1? MX\TRW5ITVJ?
HEL cell M1HTU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVr5bFlnUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlI3PzZizszN NFXNW3RUSU6JRWK=
D-566MG cell NVu0SWM2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmraTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{OzR7MTFOwG0> MWnTRW5ITVJ?
U031 cell NX;YXI5OT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3nB[2lvcGmkaYTpc44hd2ZiaIXtZY4hXTB|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOFE5OTZizszN M4HYXXNCVkeHUh?=
COR-L23 cell M3rwcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYi5UIdrUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi52M{O0OkDPxE1? M4TleHNCVkeHUh?=
NCI-H2452 cell NGPxfo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mk\YTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK0OVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjV{MkixJO69VQ>? NITOT|ZUSU6JRWK=
BB65-RCC cell M1rx[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3f2cGlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ4NT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ2NUmg{txO NF;VU|RUSU6JRWK=
CAL-33 cell NHLzfXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF7QOpFKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjV4NkWg{txO NIr6b4VUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development L.L.C. November 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products0

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID